Self-Expanding Polytetrafluoroethylene Covered Nitinol Stents for the Treatment of Ureteral Stenosis: Preliminary Report

Arguiñarena, Francisco Javier Trueba; Busto, E. Fernández del

doi:10.1097/01.ju.0000130674.86474.7f

Cited by 33 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Variable patency rates (51.2 to 100%) are reported for various types of metallic ureteral stents used in the treatment of ureteral obstruction irrespective of cause [15,17,22,23]. In our study, the UVENTA stents were not obstructed during follow-up, so that the overall patency rate was 100%.…”

Section: Discussionmentioning

confidence: 55%

Palliative Care of Malignant Ureteral Obstruction with Polytetrafluoroethylene Membrane-Covered Self-Expandable Metallic Stents: Initial Experience

Kim¹,

Song²,

Jo³

et al. 2012

Korean J Urol

View full text Add to dashboard Cite

PurposeWe assessed the efficacy and safety of insertion of a polytetrafluoroethylene membrane-covered self-expandable metallic stent (UVENTA stent) for palliation of malignant ureteral obstruction on the basis of our early results.Materials and MethodsEighteen patients underwent UVENTA stent insertion for extrinsic malignant ureteral obstructions of 20 ureters. The UVENTA stents were deployed retrogradely under cystoscopy and fluoroscopy. Candidates for the procedure had preexisting double-J stents that were nonfunctional or caused excessive bladder irritation. We recorded the success and patency rate in addition to any complications associated with the procedure.ResultsThe mean length of obstruction was 10.6 cm (range, 2 to 20 cm). Two ureters were obstructed in the upper ureter, 9 in the lower ureter, and 9 in multiple levels of ureter. Simultaneous balloon dilation was performed in 12 ureters. UVENTA stents were successfully inserted in all patients. No obstruction of the UVENTA stents occurred during the mean follow-up period of 7.3 months (patency rate 100%), but de novo ureteral obstruction developed in 4 ureters. There were no instances of stone formation, hyperplastic reaction, encrustation, or migration. Abnormally elevated serum creatinine decreased to normal levels and hydronephrosis gradually resolved during the 4 weeks after UVENTA insertion. No significant complications developed except for transient and self-limiting hematuria and mild lower abdominal pain.ConclusionsUVENTA stents may relieve malignant ureteral obstruction safely and easily. Long-term follow-up is necessary to assess the role of this stent in the treatment of malignant ureteral obstruction.

show abstract

Section: Discussionmentioning

confidence: 55%

Palliative Care of Malignant Ureteral Obstruction with Polytetrafluoroethylene Membrane-Covered Self-Expandable Metallic Stents: Initial Experience

Kim¹,

Song²,

Jo³

et al. 2012

Korean J Urol

View full text Add to dashboard Cite

show abstract

“…The studies were published over a period of 23 years (1992–2016) and included 21 prospective and 10 retrospective studies. These studies reported the effectiveness of specific MSs in population studies [1] , [2] , [3] , [5] , [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , in comparative studies between different MSs [28] and between MSs and JJ stents [29] , [30] . It should be noted that all comparative studies were retrospective in nature.…”

Section: Resultsmentioning

confidence: 99%

The effectiveness of ureteric metal stents in malignant ureteric obstructions: A systematic review

Kallidonis

Kotsiris

Sanguedolce

et al. 2017

Arab Journal of Urology

View full text Add to dashboard Cite

ObjectiveTo review the literature on the effectiveness, safety and long-term patency of ureteric metal mesh stents (MSs), as a variety of MSs have been used for managing malignant ureteric obstruction over the last three decades.Materials and methodsA systematic review using the search string; Ureter∗ AND (stent OR endoprosthesis) AND metal∗ was conducted on PubMed, Scopus, Web of science and Cochrane Library online databases in May 2016. Prospective, retrospective, and comparative studies including MSs were included. The primary endpoint was the patency rate and the secondary endpoint was complications.ResultsIn all, 324 publications were screened and 31 articles were included in the systematic review; 21 prospective and 10 retrospective studies. These studies reported the effectiveness of specific MSs in population studies, in comparative studies among different MSs, as well as among MSs and JJ stents. It should be noted that all comparative studies were retrospective.ConclusionThe experiences with vascular MSs, such as the Wallstent™ (Boston Scientific/Microvasive, Natick, MA, USA), were related to high occlusion rates, due to endoluminal hyperplasia, and long-term disappointing patency. The use of covered MSs designed for the vascular system was also unfavourable. The Memokath 051™ (PNN Medical A/S, Kvistgaard, Denmark) had better patency rates, but also higher migration rates. The long-term results were acceptable and rendered the Memokath 051 as a viable option for the management of malignant ureteric obstruction. The Uventa™ (Taewoong Medical, Seoul, Korea) and Allium™ (Allium Medical Solutions Ltd, Caesarea, Israel) MSs, specifically designed for ureteric placement, provided promising results. Nevertheless, the wide acceptance of these MSs would require well-designed clinical studies and long-term follow-up.

show abstract

“…Urinary obstruction in conjunction with the foreign material of the stent and incrustations are also risk factors for recurrent urinary tract infections, resulting in lumbar pain, hematuria, dysuria, and fever. To overcome the drawbacks of a nitinol mesh stent in the urinary tract, polytetrafluoroethylene-covered nitinol stents were developed and had promising short-term results [ 15 ]; however, distal migration of such stents poses a considerable problem [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

Endoscopic Removal of a Nitinol Mesh Stent from the Ureteropelvic Junction after 15 Years

Smrkolj

Šalinović

2015

Case Reports in Urology

View full text Add to dashboard Cite

We report a rare case of a patient with a large stone encrusted on a nitinol mesh stent in the ureteropelvic junction. The stent was inserted in the year 2000 after failure of two pyeloplasty procedures performed due to symptomatic ureteropelvic junction stenosis. By combining minimally invasive urinary stone therapies—extracorporeal shock wave lithotripsy, semirigid ureterorenoscopy with laser lithotripsy, and percutaneous nephrolithotomy—it was possible to completely remove the encrusted stone and nitinol mesh stent that was implanted for 15 years, rendering the patient symptom and obstruction free.

show abstract

Self-Expanding Polytetrafluoroethylene Covered Nitinol Stents for the Treatment of Ureteral Stenosis: Preliminary Report

Cited by 33 publications

References 12 publications

Palliative Care of Malignant Ureteral Obstruction with Polytetrafluoroethylene Membrane-Covered Self-Expandable Metallic Stents: Initial Experience

Palliative Care of Malignant Ureteral Obstruction with Polytetrafluoroethylene Membrane-Covered Self-Expandable Metallic Stents: Initial Experience

The effectiveness of ureteric metal stents in malignant ureteric obstructions: A systematic review

Endoscopic Removal of a Nitinol Mesh Stent from the Ureteropelvic Junction after 15 Years

Contact Info

Product

Resources

About